Workshop Organized by IABS

Scientific Committee

Glyn Stacey,
Division of Advanced Therapies, NIBSC-MHRA, United Kingdom
Steven Bauer,
Office of Gene and Cell Therapy Products, FDA-CBER
Karin Hoogendoorn,
Quality RA B.V., The Netherlands
Maura Kibbey,
US Pharmacopeia, USA
Ivana Knezevic,
World Health Organisation, Switzerland
Anthony Lubiniecki,
Pharmaceutical Development & Manufacturing Sciences, Janssen R&D, LLC, U.S.A.
Nick Medcalf,
University of Loughborough, UK
Yoji Sato,
National Institute of Health Sciences, Japan
Gerald Schumann,
Paul-Ehrlich-Institut, Germany
Jean-Yves Trouvin,
University Paris Descartes, France
Bao-Zhu Yuan,
National Institutes for Food and Drug Control, China

Meeting management:


Geneva, Switzerland

Objectives of the Workshop


The 2016 Cell Therapy conference will identify the key issues to be addressed for the manufacture of cell therapies and provide scientific consensus on selected aspects to inform the drafting of future guidance. The meeting will bring together representatives from industry, academia, health services and regulatory bodies. It is intended that the conference output should provide core elements that will be useful in establishing international consensus on the requirements for manufacture of cell based medicines and enable progress towards a potential future WHO endorsed guidance.